|
PSCI-18-112 |
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC) |
|
PSCI-18-131 |
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis |
|
PSCI-18-143 |
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR |
|
PSCI-19-021 |
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS) |
|
PSCI-19-039 |
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination with either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors |
|
PSCI-19-047 |
Phase 1/2 Study to Evaluate Palbociclib (Ibrance?) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors |
|
PSCI-19-049 |
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors |
|
PSCI-19-053 |
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors |
|
PSCI-19-079 |
Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC Study) |
|
PSCI-19-097 |
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001) |
